56 related articles for article (PubMed ID: 1630156)
1. Hepatic cytochrome P-4503A (CYP3A) activity in the elderly.
Hunt CM; Westerkam WR; Stave GM; Wilson JA
Mech Ageing Dev; 1992 Jun; 64(1-2):189-99. PubMed ID: 1630156
[TBL] [Abstract][Full Text] [Related]
2. A single dose of methadone inhibits cytochrome P-4503A activity in healthy volunteers as assessed by the urinary cortisol ratio.
Boulton DW; Arnaud P; DeVane CL
Br J Clin Pharmacol; 2001 Apr; 51(4):350-4. PubMed ID: 11318772
[TBL] [Abstract][Full Text] [Related]
3. Pyrotinib in
Zhou C; Li X; Wang Q; Gao G; Zhang Y; Chen J; Shu Y; Hu Y; Fan Y; Fang J; Chen G; Zhao J; He J; Wu F; Zou J; Zhu X; Lin X
J Clin Oncol; 2020 Aug; 38(24):2753-2761. PubMed ID: 32614698
[TBL] [Abstract][Full Text] [Related]
4. Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.
Ma F; Ouyang Q; Li W; Jiang Z; Tong Z; Liu Y; Li H; Yu S; Feng J; Wang S; Hu X; Zou J; Zhu X; Xu B
J Clin Oncol; 2019 Oct; 37(29):2610-2619. PubMed ID: 31430226
[TBL] [Abstract][Full Text] [Related]
5. Use of 4β-Hydroxycholesterol Plasma Concentrations as an Endogenous Biomarker of CYP3A Activity: Clinical Validation in Individuals With Type 2 Diabetes.
Gravel S; Chiasson JL; Gaudette F; Turgeon J; Michaud V
Clin Pharmacol Ther; 2019 Oct; 106(4):831-840. PubMed ID: 31002385
[TBL] [Abstract][Full Text] [Related]
6. Physiologically Based Pharmacokinetic Modeling in Regulatory Science: An Update From the U.S. Food and Drug Administration's Office of Clinical Pharmacology.
Grimstein M; Yang Y; Zhang X; Grillo J; Huang SM; Zineh I; Wang Y
J Pharm Sci; 2019 Jan; 108(1):21-25. PubMed ID: 30385284
[TBL] [Abstract][Full Text] [Related]
7. Improved Predictions of Drug-Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A.
Yadav J; Korzekwa K; Nagar S
Mol Pharm; 2018 May; 15(5):1979-1995. PubMed ID: 29608318
[TBL] [Abstract][Full Text] [Related]
8. Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation.
Hu YF; Qiu W; Liu ZQ; Zhu LJ; Liu ZQ; Tu JH; Wang D; Li Z; He J; Zhong GP; Zhou G; Zhou HH
Clin Exp Pharmacol Physiol; 2006 Nov; 33(11):1093-8. PubMed ID: 17042920
[TBL] [Abstract][Full Text] [Related]
9. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.
Gorski JC; Jones DR; Haehner-Daniels BD; Hamman MA; O'Mara EM; Hall SD
Clin Pharmacol Ther; 1998 Aug; 64(2):133-43. PubMed ID: 9728893
[TBL] [Abstract][Full Text] [Related]
10. Development of a PBPK model to quantitatively understand absorption and disposition mechanism and support future clinical trials for PB-201.
Zhang M; Lei Z; Yu Z; Yao X; Li H; Xu M; Liu D
CPT Pharmacometrics Syst Pharmacol; 2023 Jul; 12(7):941-952. PubMed ID: 37078371
[TBL] [Abstract][Full Text] [Related]
11. Prediction of pyrotinib exposure based on physiologically-based pharmacokinetic model and endogenous biomarker.
Zhang M; Yu Z; Yao X; Lei Z; Zhao K; Wang W; Zhang X; Chen X; Liu D
Front Pharmacol; 2022; 13():972411. PubMed ID: 36210839
[TBL] [Abstract][Full Text] [Related]
12. Tacrolimus Dose-Conversion Ratios Based on Switching of Formulations for Patients with Solid Organ Transplants.
Kuan WJ; Châteauvert N; Leclerc V; Drolet B
Can J Hosp Pharm; 2021; 74(4):317-326. PubMed ID: 34602619
[TBL] [Abstract][Full Text] [Related]
13. Development of a physiologically based pharmacokinetic (PBPK) population model for Chinese elderly subjects.
Cui C; Valerie Sia JE; Tu S; Li X; Dong Z; Yu Z; Yao X; Hatley O; Li H; Liu D
Br J Clin Pharmacol; 2021 Jul; 87(7):2711-2722. PubMed ID: 33068053
[TBL] [Abstract][Full Text] [Related]
14. Dose selection of chloroquine phosphate for treatment of COVID-19 based on a physiologically based pharmacokinetic model.
Cui C; Zhang M; Yao X; Tu S; Hou Z; Jie En VS; Xiang X; Lin J; Cai T; Shen N; Song C; Qiao J; Zhang S; Li H; Liu D
Acta Pharm Sin B; 2020 Jul; 10(7):1216-1227. PubMed ID: 32834950
[TBL] [Abstract][Full Text] [Related]
15. Short- and medium-term impact of bariatric surgery on the activities of CYP2D6, CYP3A4, CYP2C9, and CYP1A2 in morbid obesity.
Rodríguez-Morató J; Goday A; Langohr K; Pujadas M; Civit E; Pérez-Mañá C; Papaseit E; Ramon JM; Benaiges D; Castañer O; Farré M; de la Torre R
Sci Rep; 2019 Dec; 9(1):20405. PubMed ID: 31892725
[TBL] [Abstract][Full Text] [Related]
16. The regulation of drug-metabolizing enzymes and membrane transporters by inflammation: Evidences in inflammatory diseases and age-related disorders.
Wu KC; Lin CJ
J Food Drug Anal; 2019 Jan; 27(1):48-59. PubMed ID: 30648594
[TBL] [Abstract][Full Text] [Related]
17. Effect of CYP3A5 and ABCB1 polymorphisms on the interaction between tacrolimus and itraconazole in patients with connective tissue disease.
Togashi M; Niioka T; Komatsuda A; Nara M; Okuyama S; Omokawa A; Abumiya M; Wakui H; Takahashi N; Miura M
Eur J Clin Pharmacol; 2015 Sep; 71(9):1091-7. PubMed ID: 26184414
[TBL] [Abstract][Full Text] [Related]
18. Knockout of mouse Cyp3a gene enhances synthesis of cholesterol and bile acid in the liver.
Hashimoto M; Kobayashi K; Watanabe M; Kazuki Y; Takehara S; Inaba A; Nitta SI; Senda N; Oshimura M; Chiba K
J Lipid Res; 2013 Aug; 54(8):2060-2068. PubMed ID: 23709690
[TBL] [Abstract][Full Text] [Related]
19. Impact of obesity on drug metabolism and elimination in adults and children.
Brill MJ; Diepstraten J; van Rongen A; van Kralingen S; van den Anker JN; Knibbe CA
Clin Pharmacokinet; 2012 May; 51(5):277-304. PubMed ID: 22448619
[TBL] [Abstract][Full Text] [Related]
20. Bariatric surgery-induced weight loss reduces hepatic lipid peroxidation levels and affects hepatic cytochrome P-450 protein content.
Bell LN; Temm CJ; Saxena R; Vuppalanchi R; Schauer P; Rabinovitz M; Krasinskas A; Chalasani N; Mattar SG
Ann Surg; 2010 Jun; 251(6):1041-8. PubMed ID: 20485142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
